Clinicians and health policy experts are closely monitoring the evolution of biosimilar adalimumab prescribing following major shifts in national drug formularies. In 2024, CVS Caremark updated its commercial formularies to prefer the biosimilar adalimumab-adaz over the originator biologic. Consequently, researchers used the RISE registry to analyze the real-world impact on prescribing patterns in community rheumatology practices across the United States. Initially, the results showed a dramatic response to these policy changes, yet the long-term sustainability of these gains remains questionable.

Notably, the study found that prescriptions for adalimumab-adaz surged from near zero to over 25% among commercially insured patients immediately after the formulary change. However, this momentum was short-lived, as prescriptions dropped by 12.3% in the following month. Among new users, the data revealed a similar trend where a 24% increase was quickly followed by a 14% decrease. Therefore, while administrative mandates can force an initial shift, they do not automatically guarantee persistent utilization of biosimilar alternatives.

Overcoming Barriers to Biosimilar Adalimumab Prescribing

Several persistent barriers continue to limit the adoption of these cost-saving therapies. Specifically, the nocebo effect—where patients experience perceived loss of efficacy or side effects due to negative expectations—frequently leads to treatment discontinuation. Moreover, the administrative burden of switching stable patients creates significant friction for rheumatology practices. In the Indian market, where adalimumab biosimilars like Exemptia have long been available, these findings underscore the need for proactive patient education to manage expectations and ensure therapy adherence.

Furthermore, data from Medicare patients showed smaller but more stable increases in prescribing without the sharp subsequent drops seen in commercial plans. This suggests that different payer structures and patient demographics may influence the success of a biosimilar transition. To improve the landscape of biosimilar adalimumab prescribing, healthcare systems must prioritize communication strategies that address patient concerns. By mitigating the psychological and logistical hurdles of switching, providers can better realize the substantial cost savings offered by biosimilar technologies.

Frequently Asked Questions

What is the primary cause of the 'switchback' phenomenon in biosimilars?

The switchback phenomenon, where patients return to the originator biologic, is often driven by the nocebo effect. Patients may report subjective symptoms or perceived lack of efficacy after switching, even when the biosimilar is pharmacologically equivalent.

How can clinicians improve the sustainability of biosimilar adoption?

Clinicians can improve adoption rates by implementing structured patient education programs. Specifically, explaining the rigorous approval process for biosimilars and managing expectations about the switch can reduce negative perceptions and improve long-term retention.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Roberts ET et al. Major U.S. Formulary Change Triggers, but Does Not Sustain, Increases in Biosimilar Adalimumab Prescribing. Arthritis Care Res (Hoboken). 2026 Feb 16. doi: 10.1002/acr.80024. PMID: 41693624.


2. Mobility Foresights. India Adalimumab Market Size and Forecasts 2031. Published August 2025.


3. Colloca L, Panaccione R, Murphy TK. The Nocebo Effect and Patient Satisfaction in Biosimilar Switching. Front Pharmacol. 2019;10:1017.